Mainz Biomed (MYNZ) director discloses 17,500-share option grant and other awards

Rhea-AI Filing Summary

Mainz Biomed N.V. director Heiner Dreismann has filed an initial ownership report showing his current equity position in the company. The filing states that he directly holds employee stock options for 17,500 ordinary shares at an exercise price of $4.95, granted with 50% vesting upon grant on 03/04/2025 and the remaining 50% vesting in two 25% installments on 03/24/2026 and 03/04/2027. He also directly holds fully vested options for 250 ordinary shares at $302.8 and 1,950 ordinary shares at $200. The report shows 0 ordinary shares held directly, so his current economic exposure is through these option awards rather than owned shares.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Dreismann Heinrich

(Last) (First) (Middle)

MAINZ BIOMED N.V.

ROBERT KOCH STRASSE 50

(Street)

MAINZ 2M 55129

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2026

3. Issuer Name and Ticker or Trading Symbol
MAINZ BIOMED N.V. [ MYNZ ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	03/04/2025	(1)	Ordinary Shares	17,500	$4.95	D
Employee Stock Option (Right to Buy)	12/21/2022	(2)	Ordinary Shares	250	$302.8	D
Employee Stock Option (Right to Buy)	11/04/2021	(2)	Ordinary Shares	1,950	$200	D

Explanation of Responses:

1. 50% of the option vested upon grant on 03/04/2025; the remaining balance vests 25% on 03/24/26 and 25% on 03/04/2027.

2. Fully vested.

	/s/ Heiner Dreismann	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Form 3 filed for Mainz Biomed (MYNZ) disclose about Heiner Dreismann’s holdings?

The Form 3 shows that director Heiner Dreismann directly holds three employee stock option awards over ordinary shares of Mainz Biomed N.V. (MYNZ) and currently holds 0 ordinary shares outright.

How many Mainz Biomed (MYNZ) shares are covered by Dreismann’s stock options?

Dreismann’s options cover 17,500 ordinary shares at $4.95, 250 ordinary shares at $302.8, and 1,950 ordinary shares at $200, all reported as directly owned derivative securities.

What is the vesting schedule for Heiner Dreismann’s largest Mainz Biomed option grant?

For the 17,500-share option granted on 03/04/2025, the filing states that 50% vested upon grant, with the remaining balance vesting 25% on 03/24/2026 and 25% on 03/04/2027.

Are all of Heiner Dreismann’s Mainz Biomed stock options fully vested?

No. The filing notes that the 17,500-share option vests over time, while the options for 250 shares at $302.8 and 1,950 shares at $200 are described as fully vested.

Does Heiner Dreismann hold Mainz Biomed (MYNZ) shares directly, apart from options?

According to the Form 3, Dreismann reports holding 0 ordinary shares directly. All reported exposure comes from his employee stock options.

Are Heiner Dreismann’s Mainz Biomed holdings reported as direct or indirect ownership?

The Form 3 classifies all reported positions—both the employee stock options and the 0 ordinary shares—as direct (D) ownership, with no indirect ownership entities disclosed.